Exhibit 10.1

TERMINATION AGREEMENT

     TERMINATION AGREEMENT (this “Agreement”) dated as of February 27, 2005 by
and among MYLAN LABORATORIES INC., a Pennsylvania corporation (“Mylan”), SUMMIT
MERGER CORPORATION, a Tennessee corporation (“Summit”), and KING
PHARMACEUTICALS, INC., a Tennessee corporation (“King”).

     WHEREAS, Mylan, Summit and King are parties to an Agreement and Plan of
Merger dated as of July 23, 2004 (the “Merger Agreement”) (capitalized terms
used but not defined herein have the meanings set forth therein); and

     WHEREAS, pursuant to Section 7.1(a) of the Merger Agreement, the Merger
Agreement may be terminated, by mutual written consent of Mylan and King, if the
Board of Directors of each so determines.

     NOW, THEREFORE, Mylan, Summit and King hereby agree as follows:

     1. Termination of Merger Agreement. Pursuant to Section 7.1(a) of the
Merger Agreement, Mylan and King consent to the termination of, and Mylan,
Summit and King hereby terminate, the Merger Agreement and abandon the Merger
contemplated thereby, with the effects described in Section 7.2 of the Merger
Agreement.

     2. Representations and Warranties of Mylan and Summit. Mylan and Summit
each represent and warrant to King that it has all requisite corporate power and
authority to enter into this Agreement and to take the actions contemplated
hereby. The execution and delivery of this Agreement and the actions
contemplated hereby have been duly authorized by all necessary corporate action
on the part of each of Mylan and Summit. This Agreement has been duly executed
and delivered by each of Mylan and Summit and constitutes a valid and binding
agreement of each of Mylan and Summit, enforceable against Mylan and Summit,
respectively, in accordance with its terms.

     3. Representations and Warranties of King. King represents and warrants to
Mylan and Summit that King has all requisite corporate power and authority to
enter into this Agreement and to take the actions contemplated hereby. The
execution and delivery of this Agreement and the actions contemplated hereby
have been duly authorized by all necessary corporate action on the part of King.
This Agreement has been duly executed and delivered by King and constitutes a
valid and binding agreement of King, enforceable against it in accordance with
its terms.

     4. Cooperation. The parties shall cooperate with each other and promptly
prepare and file all necessary documentation to withdraw all applications,
notices, petitions and filings made with, and shall use their reasonable efforts
to terminate any proceedings (other than any pending litigation) before, any
Governmental Entities in connection with the Merger Agreement.

 

--------------------------------------------------------------------------------

 

     5. Entire Agreement. This Agreement constitutes the entire agreement, and
supersedes all prior agreements and understandings, both written and oral, among
the parties with respect to the subject matter of this Agreement.

     6. Counterparts. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each of
the parties and delivered (including by facsimile) to the other parties.

     7. Amendment. This Agreement may not be amended except by an instrument in
writing signed on behalf of each of the parties hereto.

     8. Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of New York, regardless of the laws that
might otherwise govern under applicable principles of conflicts of laws thereof,
except for such provisions where Tennessee law is mandatorily applicable, which
provisions shall be governed by and construed in accordance with the laws of the
State of Tennessee.

*    *    *    *    *

2

--------------------------------------------------------------------------------

 

     IN WITNESS WHEREOF, the parties have executed and delivered this Agreement
as of the date set forth above.

              MYLAN LABORATORIES INC.         By:      /s/ Robert J. Coury

--------------------------------------------------------------------------------

Name:  Robert J. Coury
Title:  Vice Chairman and Chief Executive Officer         KING PHARMACEUTICALS,
INC.
By:      /s/ Brian Markison

--------------------------------------------------------------------------------

Name:  Brian Markison
Title:  Chief Executive Officer         SUMMIT MERGER CORPORATION         By:
     /s/ Robert J. Coury

--------------------------------------------------------------------------------

Name:  Robert J. Coury
Title:  Chief Executive Officer    

3